EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access

Perispinal Etanercept to improve STroke Outcomes (PESTO): Protocol for a multicenter, international, randomized placebo-controlled trial

Vincent Thijs, Geoffrey C Cloud, Nigel Gilchrist, Brooke Parsons, Forum Tilvawala iD, Jan Ho, Lara Ruthnam, Vimal Stanislaus, Nikola Sprigg, Marion Walker, Philip M Bath, Leonid Churilov und 1 weitere

European Stroke Journal · 2024

DOI: 10.1177/23969873241249248 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift European Stroke Journal, 2024. Verfasst von Vincent Thijs und 12 weiteren Autor:innen. Beteiligte Einrichtung: Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, VIC, Australia. Hauptthemen laut MEDLINE: Etanercept, Quality of Life, Stroke. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Future Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rationale

A large proportion of stroke survivors will have long-lasting, debilitating neurological impairments, yet few efficacious medical treatment options are available. Etanercept inhibits binding of tumor necrosis factor to its receptor and is used in the treatment of inflammatory conditions. Perispinal subcutaneous injection followed by a supine, head down position may bypass the blood brain barrier. In observational studies and one small randomized controlled trial the majority of patients showed improvement in multiple post stroke impairments.

Aim

Perispinal Etanercept to improve STroke Outcomes (PESTO) investigates whether perispinal subcutaneous injection of etanercept improves quality of life and is safe in patients with chronic, disabling, effects of stroke. Methods and design: PESTO is a multicenter, international, randomized placebo-controlled trial. Adult participants with a history of stroke between 1 and 15 years before enrollment and a current modified Rankin scale between 2 and 5 who are otherwise eligible for etanercept are randomized 1:1 to single dose injection of etanercept or placebo. Study outcomes: The primary efficacy outcome is quality of life as measured using the Short Form 36 Health Inventory at day 28 after first injection. Safety outcomes include serious adverse events. Sample size target: A total of 168 participants assuming an improvement of the SF-36 in 11% of participants in the control arm and in 30% of participants in the intervention arm, 80% power and 5% alpha.

Discussion

PESTO aims to provide level 1 evidence on the safety and efficacy of perispinal etanercept in patients with long-term disabling effects of stroke.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EtanerceptQuality of LifeStrokeAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodInjections, SubcutaneousTreatment OutcomeMulticenter Studies as TopicRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

RCTStrokeTNF-alphachronic effects of strokeetanerceptimproving chronic effects of strokeperispinalplaceborandomized controlled trialstroke outcomes

Substanzen

Etanercept

Autor:innen und Institutionen

  • Florey Institute of Neuroscience and Mental Health, University of Melbourne, Heidelberg, VIC, Australia.
  • Department of Neurology, Austin Health, Heidelberg, VIC, Australia.
  • Department of Medicine, Melbourne Medical School, University of Melbourne, Heidelberg/Parkville, VIC Australia.
  • Department of Neuroscience, Central Clinical School, Monash University Melbourne, Melbourne, VIC, Australia.
  • Department of Neurology, Alfred Health, Melbourne, VIC, Australia.
  • CGM Research Trust, Christchurch, New Zealand.

ORCID-Profile: Forum Tilvawala

Förderung

  • Medical Research Future Fund

Zitieren

APA

Thijs, V., Cloud, G. C., Gilchrist, N., Parsons, B., Tilvawala, F., Ho, J., Ruthnam, L., Stanislaus, V., Sprigg, N., Walker, M., Bath, P. M., Churilov, L., & Bernhardt, J. (2024). Perispinal Etanercept to improve STroke Outcomes (PESTO): Protocol for a multicenter, international, randomized placebo-controlled trial. European Stroke Journal. https://doi.org/10.1177/23969873241249248

Vancouver

Thijs V, Cloud GC, Gilchrist N, Parsons B, Tilvawala F, Ho J, et al. Perispinal Etanercept to improve STroke Outcomes (PESTO): Protocol for a multicenter, international, randomized placebo-controlled trial. European Stroke Journal. 2024. doi:10.1177/23969873241249248

BibTeX
@article{Thijs2024,
  author = {Thijs, Vincent and Cloud, Geoffrey C and Gilchrist, Nigel and Parsons, Brooke and Tilvawala, Forum and Ho, Jan and Ruthnam, Lara and Stanislaus, Vimal and Sprigg, Nikola and Walker, Marion and Bath, Philip M and Churilov, Leonid and Bernhardt, Julie},
  title = {Perispinal Etanercept to improve STroke Outcomes (PESTO): Protocol for a multicenter, international, randomized placebo-controlled trial},
  journal = {European Stroke Journal},
  year = {2024},
  doi = {10.1177/23969873241249248}
}
Kostenlos starten →